Table 3.
Summary of adverse events
| Toxicity | Number of patients (BEAV) N=20 (%) | Number of patients (Non BEAV) N=21 (%) | ||
|---|---|---|---|---|
|
|
|
|||
| Any grade | Grade 3-4 | Any grade | Grade 3-4 | |
| Summary | 20 (100%) | 11 (55.0%) | 21 (100%) | 8 (38.1%) |
| Hypertension | 12 (60.0%) | 1 (5.0%) | 7 (33.3%) | 1 (4.8%) |
| Thrombocytopenia | 10 (50.0%) | 1 (5.0%) | 6 (28.6%) | 0 (0%) |
| Fatigue | 9 (45.0%) | 0 (0%) | 6 (28.6%) | 1 (4.8%) |
| Abnormal liver function | 8 (40.0%) | 1 (5.0%) | 9 (42.9%) | 1 (4.8%) |
| Nausea | 7 (35.0%) | 0 (0%) | 5 (23.8%) | 0 (0%) |
| Mucosal inflammation | 7 (35.0%) | 1 (5.0%) | 7 (33.3%) | 0 (0%) |
| Anemia | 7 (35.0%) | 1 (5.0%) | 6 (28.6%) | 1 (4.8%) |
| Proteinuria | 6 (30.0%) | 1 (5.0%) | 5 (23.8%) | 0 (0%) |
| Thrombocytopenia | 6 (30.0%) | 0 (0%) | 6 (28.6%) | 0 (0%) |
| Diarrhea | 6 (30.0%) | 1 (5.0%) | 5 (23.8%) | 1 (4.8%) |
| Vomiting | 6 (30.0%) | 0 (0%) | 5 (23.8%) | 1 (4.8%) |
| Asthenia | 6 (30.0%) | 1 (5.0%) | 7 (33.3%) | 0 (0%) |
| Abdominal pain | 6 (30.0%) | 1 (5.0%) | 8 (38.1%) | 0 (0%) |
| Constipation | 5 (25.0%) | 0 (0%) | 4 (19.0%) | 1 (4.8%) |
| Skin rash | 5 (25.0%) | 1 (5.0%) | 4 (19.0%) | 0 (0%) |
| Leukopenia | 5 (25.0%) | 0 (5.0%) | 4 (19.0%) | 0 (0%) |
| Pain in extremity | 5 (25.0%) | 0 (0%) | 3 (12.8%) | 0 (0%) |
| Epistaxis | 4 (20.0%) | 0 (0%) | 2 (9.5%) | 1 (4.8%) |
| Gastrointestinal perforation | 1 (5.0%) | 1 (5.0%) | 0 (0%) | 0 (0%) |